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TO THE EDITOR
The Philadelphia (Ph) chromosome which characterises chronic myeloid leukaemia (CML) is created by a balanced reciprocal t(9;22)(q34;q11) translocation, in which the ABL and BCR genes are disrupted, to form a BCR-ABL fusion gene. In the vast majority of cases, the breakpoints in the BCR gene on chromosome 22 are in the major breakpoint cluster region (M-bcr), a 5.8 kilobase (kb) region spanning 5 exons originally designated b1-b5 (now also designated e12-e16). Rare cases of CML have a BCR breakpoint considerably more 3Ј than M-BCR, located in the (-bcr region, resulting in an e19a2 fusion transcript, which encodes for a longer 230 kDa BCR-ABL protein. e19a2 CML has been associated with chronic neutrophilic leukaemia (CNL). CNL is a rare myeloproliferative disorder which is typified by a lower peripheral blood (PB) white count, a lower proportion of PB neutrophil precursors, less severe anaemia, and less prominent splenomegaly at initial presentation, and a lower probability of disease progression. 1 We now report two cases of e19a2-positive CML, in which a variant BCR-ABL transcript was identified containing an in-frame deletion of the whole of exon e16. Such a rearrangement has not to our knowledge been previously reported.
A 52-year-old previously healthy woman was diagnosed with CML in July 1996. The white blood cell count at diagnosis was 450 × 10 9 /l, with a differential of 36% neutrophils, 2% lymphocytes, 2% monocytes, 3% eosinophils, 1% basophils, 28% metamyelocytes, 10% myelocytes, 5% promyelocytes, 13% blasts, and the haemoglobin concentration was 8.7 g/dl. The spleen was 4 cm below the costal margin. At this time all 10 metaphases examined showed 47XX,t(9,22)(q34;q11), +der(22)t(9;22)(q34;q11). She was initially treated with hydroxyurea and interferon, but did not achieve a cytogenetic response after 7 months of treatment and interferon was discontinued. She developed lymphoid blast crisis in April 1998, and marrow cytogenetics at that time revealed an additional clone with a complex karyotype including deletions in 3p and 6q, and monosomy 7. She achieved a second chronic phase (CP) after treatment with vincristine and prednisolone. She received ALL maintenance chemotherapy until November 1998, when she developed a second lymphoid blast crisis, associated with the same complex karyotype. Following treatment with daunorubicin, vinblastine and steroids she achieved a third CP. She underwent transplantation in March 1999, using standard BuCy conditioning and with cryopreserved autologous first CP stem cells as the graft. On haemopoietic recovery she was maintained on hydroxyurea alone. In December 2000, all 30 metaphases examined showed 47XX,t(9,22)(q34;q11), +der(22)t(9;22)(q34;q11), with no evidence of the complex karyotype associated with the blast crisis.
The second case was a 61-year-old previously well man, who was found to have CML at a routine medical in July 1998. At diagnosis the platelet and white blood cell counts were 485 and 21.9 × 10 9 /l respectively (white cell differential = neutrophils 14.9, lymphocytes 2.6, monocytes 2.0, eosinophils 0.7, myelocytes 1.3 and basophils 0.4 ϫ10 9 /l). The spleen was palpable 1 cm below the costal margin. At diagnosis his karyotype was 46,XY,t(9;22)(q34;q11) in all 12 metaphases examined. He was initially treated with pegylated interferon, but this did not achieve haematological control and was discontinued in January 2000. He was then controlled on hydroxyurea. In May 2001, his karyotype revealed 45,X,−Y,der(9)t(9;22)(q34;q11), ider Molecular analysis was carried out on peripheral blood leukocytes taken in December 2000 (case 1) and May 2001 (case 2). No material was available from earlier in the disease in either patient. cDNA was amplified by PCR using primers EK158 and EK159 as described previously. 2 On running the PCR product on 1% agarose, two discrete bands were found, corresponding to 860 and 728 base pairs (bp). The intensity of the 728 bp band was less than 10% of that of the 860 bp band. Both bands were cut from agarose gel, cloned into expression vectors, and sequenced. The sequence of the 860 bp fragment corresponded to that of the BCR-ABL e19a2 transcript. The 728 bp fragment had the same sequence as the intact e19a2 transcript, except that the entire 132 bp of BCR exon e16 (also known as exon b5) were deleted. Since the sample from case 2 showed similar molecular features to case 1, in order to exclude the possibility of cross-contamination in PCR reactions we examined a fresh sample taken about 4 weeks later, and processed separately from other CML samples. The molecular findings remained unchanged.
A total of 15 cases of e19a2-positive CML have been reported. 3, 4 Although the initial reports emphasized the good outlook of CNL, subsequent reports have described p230 in classical CML. The clinical behaviour of e19a2-positive CML therefore appears variable. We now report two further cases of e19a2-positive CML. The presentation features and the development of blast crisis at 21 months in case 1 are compatible with classical CML, rather than CNL. These cases contribute to the emerging picture of e19a2-positive CML in two ways. Firstly, at the time of molecular study, each case has an additional Ph chromosome. This cytogenetic feature is often indicative of disease progression, and is unusual in chronic phase CML. An additional Ph chromosome was reported in four of the eight published cases of e19a2-positive CML in which cytogenetic data are available. 3, 4 Together with the present cases, 60% of cases have an additional Ph chromosome, suggesting that this lesion may be more prevalent in e19a2-positive CML. Secondly, each of the present cases has a transcript containing a novel in-frame deletion of the whole of exon e16. Analysis of the 728 bp sequence indicated that the deletion did not cause a frameshift. Analogous though not identical deletions have been previously reported. Wada et al 5 described a case of Ph-positive CML with an e19a2 transcript and an additional transcript with a BCRc2/ABL junction (corresponding to e18a2 transcript). Mittre et al 6 reported a case of Ph-positive CML with c1a2 (e17a2) and c2a2 (e18a2) transcripts co-existing with the e19a2 transcript. In both the e17a2 and e18a2 transcript, a frameshift arose at the junction, leading to a stop signal shortly after the junction. e19a2 transcripts may therefore exhibit considerable heterogeneity at the molecular level.
In summary, we present two cases of e19a2-positive CML with an additional Ph chromosome, and in whom the abnormal transcript contains a novel in-frame deletion of the whole of exon e16. Taken with previously reported patients, the present cases support the view that there may be molecular heterogeneity in the e19a2 transcript/protein, and this may correlate with the variable clinical course reported in e19a2 positive CML. TO THE EDITOR Dysplasia of erythroid, granulocytic and megakaryocytic lineages is the diagnostic hallmark of myelodysplastic syndrome (MDS). The usual result is one or more peripheral blood cytopenias and an increased risk of leukemic transformation. Transcription factors play a key role in controlling the cellular proliferation and differentiation of hematopoietic stem cells. 1,2 GATA-1 and GATA-2 are zinc-finger transcription factors that play an important role in gene regulation during development and differentiation of hematopoietic cells. Previous studies using GATA-1 and GATA-2 knock-out mice showed that GATA-2 gene inactivation caused partial deficiency in the production of hematopoietic lineages through its action in early progenitor or stem cell proliferation, 2 while GATA-1 was important for erythroid differentiation of hematopoietic progenitor cells. 3 The expression of GATA family genes and its implication in primary MDS has never been reported. Since inappropriate hematopoietic differentiation results in varying degree of myelodysplasia, which is the hallmark of MDS, we hypothesized that mRNA expression patterns of GATA-1 and GATA-2 are associated with MDS, and possibly with the severity of these diseases.
In this study, bone marrow (BM) specimens were obtained from 45 adult patients with primary MDS, including 24 patients with refractory anemia with excess of blasts or refractory anemia with excess of blasts in transformation (RAEB/RAEBT) and 21 patients with refractory anemia or refractory anemia with ring sideroblasts (RA/RARS). Peripheral blood (PB) samples from three normal individuals and BM specimens from eight patients with non-hematological diseases were used as controls. Two independent hematologists examined the BM aspirate specimens and trephine biopsy sections. Morphological features that were used to indicate dyserythropoiesis, dysgranulopoiesis and dysmegakaryopoiesis were based on the FAB group 4 (Table 1) . A scoring system based on features listed in Table 1 was developed to split the MDS patients into two groups morphologically according to the severity of myelodysplasia: severe or minimal dysplasia. The presence of less than one-third of the features was considered to be minimal dysplasia. This scoring system has been shown to correlate well with the degree of peripheral cytopenias in MDS; in addition, patients with severe dysplasia are more likely to be transfusion dependent (unpublished observations).
GATA-1 and GATA-2 gene expression was determined by using Superscript one-step RT-PCR system (Gibco BRL, Gaithersburg, MD, USA). 5 The primers used in this study were human GATA-1 (forward We detected GATA-1 in only five of the 45 MDS patients (11.1%) and GATA-2 in 40 patients (88.9%) (Figure 1 ). Since GATA-1 expression may be auto-regulated or controlled by other GATA family members including GATA-2, 11,12 we attempted to divide the MDS patients into one of the following four groups according to the expression of GATA-1 and GATA-2 genes; GATA-1
We identified 35 (77.8%) MDS patients with a GATA-1 − GATA-2 + expression pattern, five patients (10.9%) were either GATA-1 Table 2 ). The expression of GATA-1 and GATA-2 was not detected in any samples obtained from hematologically normal control subjects; in addition, the results obtained from MDS samples were identical irrespective of the source of cells (BM or PB). These indicate that the cells used were free of contaminating erythroblasts, thus GATA expression is in the lymphoid population and the cells isolated from individuals with normal hematopoiesis did not express these genes. Therefore, the current results are likely to represent characteristics of MDS cells rather than contaminating erythroid or progenitor cells.
Thirty-three (73.3%) MDS patients exhibited severe dysplasia of erythroid, granulocytic and megakaryocytic lineages, while the remaining 12 patients had minimal dysplasia. Most patients (28 of 33; 84.8%) who showed severe dysplasia were GATA-1 − GATA-2 + , and the remaining five patients were GATA-1
In contrast, all patients with GATA-1 and GATA-2 coexpression had minimal dysplasia. We did not observe any correlation between the pattern of GATA expression and FAB subtype (Table 2 ) or karyotype (data not shown). These results, although based on a small number of patients, suggest that dysregulation of GATA gene expression is a feature of myelodysplastic hematopoiesis and that the pattern of expression is linked to the degree of dysplasia (P Ͻ 0.05).
The coordination of several transcription factors is essential in the development of normal hematopoiesis. 13, 14 The observations derived from GATA-1 and GATA-2 gene knockouts support a hypothesis that these transcription factors act successively and co-operatively with overlapping and unique functions during normal erythropoieisis. In stem cells or early hematopoietic progenitors, GATA-2 expression predominates to promote cellular proliferation. Rising levels of GATA-1 suppress GATA-2 expression by an unknown mechanism and sustain GATA-1 expression through positive autoregulation. The shift from GATA-2 to GATA-1 predominance tips the cellular balance in favor
